Risk-based management of prostate cancer

New England Journal of Medicine

Volumn 365, Issue 2, 2011, Pages 169-171

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CANCER SURVIVAL; EDITORIAL; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL DISEASE; GLEASON SCORE; HOT FLUSH; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; RASH; RISK MANAGEMENT; UROGENITAL TRACT DISEASE;

EID: 79960204346     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1103829     Document Type: Editorial

References (10)

1. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-73.
2. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8. [Erratum, Lancet 2009;373:1174.]
3. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451-9.
4. D'Amico AV, Chen M, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-95. (Pubitemid 351159365)
5. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-18.
6. FDA note to correspondents: include warnings on risk for class of prostate cancer drugs. Silver Spring, MD: Food and Drug Administration, 2010. (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230334.htm.)
7. Nanda A, Chen M, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866-73.
8. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
9. Nguyen PL, Chen MH, Beard CJ, et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010;77:1046-52.
10. Armstrong JG, Gillham CM, Dunne MT, et al. A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2010 August 24 (Epub ahead of print).